Biotech startup Pheast Therapeutics is out of stealth taking a tack similar to that of cancer immunotherapy company Forty Seven, also a spinout from the Stanford University lab of Irving Weissman. While both companies get immune cells to eat tumors, Pheast’s technology has the potential to take the approach to a broader range of cancer types including those that have historically resisted immunotherapy.
/PRNewswire/ Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, today announced it has raised $76 million in Series A.
Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Fred Hutch announces 2022 Harold M Weintraub Graduate Student Award recipients fredhutch.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fredhutch.org Daily Mail and Mail on Sunday newspapers.